Embryosafe assess embryo health by testing for aneuploidies (PGT-A), chromosomal structural abnormalities (PGT-SR), and monogenic diseases (PGM-M). It helps identify the most viable embryos, reducing the risk of miscarriage and genetic disorders.
PGT-A detects chromosomal abnormalities such as trisomy and monosomy, improving implantation success and reducing miscarriage rates in IVF. It also identifies mosaic embryos, which contain both euploid and aneuploid cells, guiding embryo selection.
PGT-SR identifies chromosomal structural rearrangements that can cause infertility, miscarriage or congenital abnormalities.
PGT-M screens for monogenic diseases such as cystic fibrosis, for selecting embryos free from inherited genetic disorders.
niEmbryoSafe
niEmbryoSafe is a non-invasive test that analyses cell-free embryonic DNA from spent culture media to assess chromosomal status without embryo biopsy, offering a viable alternative to traditional PGT-A.
PGT-A Next (the Ploidy test)
PGT-A Next for Ploidy extends traditional PGT-A/SR by analysing chromosomal ploidy, identifying embryos with a normal diploid set, even if they initially appeared morphologically abnormal. It is indicated for abnormal fertilisation patterns, previous polyploid or triploid pregnancies, recurrent miscarriages linked to polyploidy or suspected diploid anomalies in IVF embryos.